Crossmark

A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s12328-024-02040-8

Published Online: 2024-10-03

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hidaka, Hisashi https://orcid.org/0000-0002-4151-5663
Kamata, Hirotoshi

Uojima, Haruki

Iwasaki, Shuichiro

Iida, Junki

Nakazawa, Takahide

Kusano, Chika
License Information

Text and Data Mining valid from 2024-10-03

Version of Record valid from 2024-10-03
More Information

Article History

Received: 5 June 2024

Accepted: 11 September 2024

First Online: 3 October 2024

Declarations

:

: The authors declare they have no conflicts of interest.

: Written informed consent was obtained from the patient for publication of this case report and the accompanying images.

Document is current

Any future updates will be listed below